Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Intratumour heterogeneity in renal and lung cancer

Ninth European International Kidney Cancer Symposium

Published: 6 May 2014

Views: 3053

Rating:

Save

Prof Charles Swanton - CRUK London Research Institute and UCL, London, UK

Prof Swanton talks to ecancertv at the EIKCS conference about his work looking at intratumour heterogeneity in renal and lung cancer.

'Intratumour heterogeneity' refers to the subpopulations of cells with distinct genomic alterations within the same solid tumour and its discovery is likely to have implications for cancer therapeutics and biomarkers.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for...

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes...

Dr Joshua Choe - Columbia University, New York City, USA

Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death ( Dr Joshua Choe - Columbia University, New York City, USA )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

ASCO Direct Highlights 2022: lung cancer highlights

Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA

ASCO Direct Highlights 2022: lung cancer highlights ( Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA )

Locally and advanced immunotherapy developments and new agents in lung cancer

Dr George Simon - Moffitt Advent Health Clinical Research Unit, Tampa, USA

Locally and advanced immunotherapy developments and new agents in lung cancer ( Dr George Simon - Moffitt Advent Health Clinical Research Unit, Tampa, USA )

More from ecancer